Latest Stock Buy or Sell? Make More Informed Decisions!

Chart's pulled back, but still participating in the rally. Great choice in the financial services sector, doing well compared even to some Canadian banks. 18% upside to street's price target. Nice upward trend, sees it continuing. Until it breaks down, she likes it.

Stable dividend of 5%. Increased loan loss provisions, squeezed with where interest rates are. Opportunity in Canadian banks, but she favours RY. More revenue coming for all banks in Q4 and 2025 with mortgage renewals. Ranks 8/10 on fundamentals.

Opportunity in Canadian banks, and this is her favoured pick. More revenue coming for all banks in Q4 and 2025 with mortgage renewals. Ranks 8/10 fundamentally, 8/10 on value. Leader among Canadian banks. When it gets too big a position, she takes some profits off the table, and then lets the rest ride.

Scores 8/10 fundamentally. One of the largest financial institutions in US, with more than $3T of assets. When it gets too big a position, she trims a bit, and then lets the profits ride.

Growth significantly driven by increased industrial activity, near-shoring is increasing demand. Benefited from higher US shipments, offsetting lower Canadian grain and coal volumes. This just reflects the stronger US economy. Strong growth in coming years. 27x is a bit expensive, but growth is higher too. Potential 11% upside from here.

Downward slope since April 2022. Value score of 9/10 is attractive, but wait to see a turnaround. Telcos and utilities should start to do better once interest rates come down. Late 2024 or early 2025 may be promising. Dividend of ~8.8% safe. If you own it, she and the street say Hold.

3/10 on value, not too attractive. Super-volatile stock. Fundamentally, 9/10. Employees are in 400 offices across 40 countries. AI boom isn't going anywhere. Valuation stretched, upside potential of 6%. Wait to see how the tech play is going before entering. Good long-term hold.

Underperforming. Great specialty beauty retailer in the US, partners with Target. Chart's a roller-coaster, too volatile for her. You can trade it if you want, get in and get out, but she's staying away.

Still bullish. Stock's around her target of $49, but she believes it's fairly valued. Street consensus ratcheted up to $58-62, another 20% higher from here. 8/10 on fundamentals and technicals. Yield is 4%.

Despite pullback, still sees positives going forward. About 22% upside to her target price. Plenty of cash that it keeps investing to continue the momentum of earnings growth. 9/10 on value, 8/10 on fundamentals. Not a core holding the way CNQ is.

Sector's low beta makes it immune to economic shocks. YOY revenue growth of 9%. New products in pipeline, promising collaborations, JV with Moderna. FDA-approved hypertension drug has great growth prospects. Forward PE of 15.4x, still attractive. Generous dividend yield of over 2%. Another 12% upside from here.

Not exactly undervalued. Volatile. Range-bound until recent uptrend. Impacted by commodity prices and interest rates. Cost-cutting, lowering forecasts. Business remains under pressure. 11% upside to street's target. Wait to see where the stock's going. Yield of 1.5%.

Looks pretty attractive. 9/10 on value, 10/10 fundamentally. On her radar. Still runway of ~15% upside from here. Beat latest EPS. Sector has more momentum and run to go. She prefers CNQ.

She prefers QCOM as a long-term hold. 9/10 on fundamentals. Small pullback presents a great entry point, still upside. Has participated in the chip rally. Wait for more of a pullback, as the broadening across other sectors will continue to bring up the market.

She prefers QCOM as a long-term hold, as it's 9/10 on fundamentals, and the pullback in QCOM presents a great entry point.